Geron saw the highest growth of 1.99% in patent filings in April and 5.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Geron‘s patent filings and grants. Buy the databook here.
Geron has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 40% filings and 12% grants. The United States(US), Chile(CL), Denmark(DK), and Spain(ES) patent Office are among the top ten patent offices where Geron is filings its patents. Among the top granted patent authorities, Geron has 25% of its grants in Spain(ES), 12% in United States(US) and 12% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Geron
Patents related to rare diseases and healthtech lead Geron's portfolio
Geron has the highest number of patents in rare diseases followed by, healthtech and genomics. For rare diseases, nearly 30% of patents were filed and 50% of patents were granted in Q2 2024.
Myelofibrosis related patents lead Geron portfolio followed by leukemia, and preleukemia
Geron has highest number of patents in myelofibrosis followed by leukemia, preleukemia, myeloproliferative disorders, and essential thrombocythemia. For myelofibrosis, nearly 25% of patents were filed and 12% of patents were granted in Q2 2024.
For comprehensive analysis of Geron's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.